Arch Biopartners Inc.
ARCH.V
TSX
12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Revenue | 219.10K | -819.30K | 86.60K | 1.87M | 320.30K |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 219.10K | -819.30K | 86.60K | 1.87M | 320.30K |
Cost of Revenue | 124.80K | -1.37M | 232.90K | 2.34M | 344.40K |
Gross Profit | 94.40K | 546.20K | -146.30K | -467.50K | -24.10K |
SG&A Expenses | 598.80K | 156.40K | 193.20K | 143.10K | 1.55M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 723.50K | -1.21M | 426.10K | 2.48M | 1.89M |
Operating Income | -504.40K | 389.80K | -339.50K | -610.60K | -1.57M |
Income Before Tax | -575.70K | 182.10K | -335.60K | -711.60K | -1.59M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -575.70K | 182.10K | -335.60K | -711.60K | -1.59M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -575.70K | 182.10K | -335.60K | -711.60K | -1.59M |
EBIT | -504.40K | 389.80K | -339.50K | -610.60K | -1.57M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -0.01 | 0.00 | -0.01 | -0.01 | -0.03 |
Normalized Basic EPS | -0.01 | 0.00 | 0.00 | -0.01 | -0.02 |
EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | -0.03 |
Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | -0.01 | -0.02 |
Average Basic Shares Outstanding | 62.47M | 63.65M | 62.24M | 62.40M | 62.34M |
Average Diluted Shares Outstanding | 62.47M | 63.65M | 62.24M | 62.40M | 62.34M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |